- £1.42bn
- £1.39bn
- $1.19bn
- 41
- 44
- 86
- 60
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 11.79 | ||
| PEG Ratio (f) | 3.2 | ||
| EPS Growth (f) | 3.82% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 16.73 | ||
| Price to Sales | 1.68 | ||
| EV to EBITDA | 16.78 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 25.41% | ||
| Return on Equity | n/a | ||
| Operating Margin | 8.2% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 647 | 791 | 901 | 1,093 | 1,188 | 1,033.03 | 1,078.24 | 8.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -5.69 | +67.67 | -31.14 | +37.56 | -13.79 | -6.95 | +14.13 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Directors
- Graham Hetherington NEC (58)
- Mark Crossley CEO
- Ryan Preblick CFO
- Jon Fogle CHO
- Christian Heidbreder CSO
- Cynthia Cetani CCO
- Murali Gopal OTH
- Richard Simkin OTH
- Jon Wasserman OTH
- Hillel West OTH
- Kathryn Hudson SEC
- Jerome Lande NED (45)
- Peter Bains NID (64)
- Joanna Le Couilliard NID
- A. Thomas McLellan NID
- Lorna Parker NID
- Daniel Phelan NID (71)
- Mark Stejbach NID (58)
- Juliet Thompson NID
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- September 26th, 2014
- Public Since
- December 23rd, 2014
- No. of Shareholders
- 1,027
- No. of Employees
- 1,030
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
London Stock Exchange- Shares in Issue
- 124,769,820
- Address
- 234 Bath Road, SLOUGH, SL1 4EE
- Web
- https://www.indivior.com/en
- Phone
- +1 8043791090
- Contact
- Jason Thompson
- Auditors
- PricewaterhouseCoopers LLP
Latest News for INDV
Upcoming Events for INDV
Half Year 2025 Indivior PLC Earnings Release
Q3 2025 Indivior PLC Earnings Release
Similar to INDV
Animalcare
London Stock Exchange
AstraZeneca
London Stock Exchange
Beximco Pharmaceuticals
London Stock Exchange
BSF Enterprise
London Stock Exchange
Celadon Pharmaceuticals
London Stock Exchange
FAQ
As of Today at 21:17 UTC, shares in Indivior are trading at 1,142.00p. This share price information is delayed by 15 minutes.
Shares in Indivior last closed at 1,142.00p and the price had moved by +35.47% over the past 365 days. In terms of relative price strength the Indivior share price has outperformed the FTSE All Share Index by +26.13% over the past year.
The overall consensus recommendation for Indivior is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreIndivior does not currently pay a dividend.
Indivior does not currently pay a dividend.
Indivior does not currently pay a dividend.
To buy shares in Indivior you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of 1,142.00p, shares in Indivior had a market capitalisation of £1.42bn.
Here are the trading details for Indivior:
- Country of listing: United Kingdom
- Exchange: LSE
- Ticker Symbol: INDV
Based on an overall assessment of its quality, value and momentum Indivior is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Indivior is 1,098.60p. That is 3.8% below the last closing price of 1,142.00p.
Analysts covering Indivior currently have a consensus Earnings Per Share (EPS) forecast of $1.22 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Indivior. Over the past six months, its share price has outperformed the FTSE All Share Index by +7.97%.
As of the last closing price of 1,142.00p, shares in Indivior were trading +35.26% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Indivior PE ratio based on its reported earnings over the past 12 months is 11.79. The shares last closed at 1,142.00p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Indivior's management team is headed by:
- Graham Hetherington - NEC
- Mark Crossley - CEO
- Ryan Preblick - CFO
- Jon Fogle - CHO
- Christian Heidbreder - CSO
- Cynthia Cetani - CCO
- Murali Gopal - OTH
- Richard Simkin - OTH
- Jon Wasserman - OTH
- Hillel West - OTH
- Kathryn Hudson - SEC
- Jerome Lande - NED
- Peter Bains - NID
- Joanna Le Couilliard - NID
- A. Thomas McLellan - NID
- Lorna Parker - NID
- Daniel Phelan - NID
- Mark Stejbach - NID
- Juliet Thompson - NID